Nitisinone 5mg Capsules

Nitisinone 5mg treats hereditary tyrosinaemia type 1, an inherited disorder that produces toxic breakdown products capable of damaging the liver and kidneys. Treatment is combined with a diet restricting tyrosine and phenylalanine.
Take the capsules on an empty stomach, at least one hour before or two hours after a meal, at consistent daily times. The dose is based on body weight and adjusted using succinylacetone results. Continue the tyrosine- and phenylalanine-restricted diet alongside treatment; the capsules do not replace dietary management.
Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase early in the tyrosine-breakdown pathway. This prevents formation of toxic downstream substances such as succinylacetone, but can increase blood tyrosine levels.
Raised tyrosine, reduced platelets or white cells, rash and nosebleeds can occur. Eye pain, redness, light sensitivity or blurred vision may be associated with high tyrosine and need prompt assessment.
Monitoring includes tyrosine, phenylalanine, succinylacetone, blood counts and liver assessment. Liver surveillance continues even when metabolic control is good. Warfarin and other sensitive CYP2C9 substrates can require closer monitoring because nitisinone can increase their exposure.
Suppressing toxic metabolites can prevent acute metabolic complications and reduce progressive liver and kidney injury. Early, sustained treatment improves long-term outcomes, while nutrition monitoring supports growth and avoids excessive amino-acid restriction.
The medicine blocks tyrosine breakdown before toxic metabolites form. Tyrosine may therefore rise even while succinylacetone falls; diet is used to control this rise.
No. Increasing enzyme blockade does not correct dietary tyrosine accumulation. The metabolic team adjusts the nutritional plan and uses succinylacetone to assess the medicine's effect.
Succinylacetone is an important marker. Blood or urine testing helps determine whether toxic metabolite production is adequately blocked.
No. Existing liver damage and the risk of liver tumours still require ongoing surveillance. Good metabolic results do not make liver imaging and related follow-up unnecessary.
HT-1: hereditary tyrosinaemia type 1. Tyrosine: amino acid controlled through the treatment diet. Phenylalanine: amino acid that can be converted to tyrosine. Succinylacetone: toxic metabolite used to monitor HT-1. HPPD: enzyme inhibited by nitisinone.; AR: Nitisinone 5mg كبسولات; FR: Nitisinone 5mg gélules; PT: Nitisinone 5mg cápsulas; ES: Nitisinone 5mg cápsulas; RU: Nitisinone 5mg капсулы; ID: Nitisinone 5mg kapsul; VI: Nitisinone 5mg viên nang; MS: Nitisinone 5mg kapsul; TL: Nitisinone 5mg kapsula; ZH-SG: Nitisinone 5mg 胶囊
International B2B Enquiry
Send a structured B2B enquiry for Nitisinone 5mg Capsules under Metabolic Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Nitisinone 5mg Capsules